Faculty

Back to Index
Andreas O. Reiff, MD
Professor of Clinical Pediatrics
Division Head, Rheumatology
Pediatrics
CHL Mail Stop 60 Off Campus Los Angeles
+1 323 361 5524

Overview

Andreas Otto Reiff, MD, is a Professor of Pediatrics at Children's Hospital Los Angeles, Keck School of Medicine and Division Head of the Division of Rheumatology at Children's Hospital Los Angeles. He is also the director of the Pediatric Rheumatology Program at Miller Children's Hospital in Long Beach, California and a Visiting Clinical Associate Professor, Department of Pediatrics, University of Nevada School of Medicine. Dr. Reiff received his medical degree from University Medical School in Freiburg, Germany. Following an internship in internal medicine and surgery at Kantonsspital Liestal in Switzerland, he returned to Freiburg and completed his residency at the University Children's Hospital. He completed a research fellowship in the Division of Rheumatology and Bone Marrow Transplantation at Childrens Hospital Los Angeles between 1993 and 1994, and a fellowship in pediatric rheumatology at University Children's Hospital in Freiburg from 1994 -1996. An avid researcher and investigator, Dr. Reiff's primary research interests include the treatment, management, and genetics of pediatric autoimmune diseases; treatment of inflammatory and degenerative eye diseases, and alternatives to stem cell transplantation. In addition to authoring and co-authoring numerous journal articles, abstracts, reviews, and book chapters, he has lectured on rheumatologic topics nationally and internationally. He is a clinical consultant for several pharmaceutical companies and serves on advisory boards for the Arthritis Foundation, Lupus International, and on several CHLA committees. He is a well known national and international speaker on biologic drug development and the treatment of chronic inflammatory eye diseases. Dr. Reiff is board-certified in pediatrics and pediatric rheumatology by the European Union and the American Board of Pediatrics. He is a member of the Southwestern Pediatric Society, the Pediatric Rheumatology Collaborative Study Group, and the American College of Rheumatology. In addition, he is a founding member of the pediatric rheumatology research network (CARRA). He has received several honors, grants, and awards.

Publications

Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. Arthritis Rheumatol. 2016 Oct; 68(10):2514-26. View in: PubMed

Transition of Care and Health-Related Outcomes in Pediatric-Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2015 Nov; 67(11):1521-8. View in: PubMed

Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res (Hoboken). 2015 May; 67(5):658-66. View in: PubMed

Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2015 May; 67(5):1377-85. View in: PubMed

Treatment of pediatric takayasu arteritis with infliximab and cyclophosphamide: experience from an american-brazilian cohort study. J Clin Rheumatol. 2014 Jun; 20(4):183-8. View in: PubMed

Rheumatic inflammatory eye diseases of childhood. Rheum Dis Clin North Am. 2013 Nov; 39(4):801-32. View in: PubMed

Preface. Rheum Dis Clin North Am. 2013 Nov; 39(4):xvii-xviii. View in: PubMed

Exome sequencing reveals RAG1 mutations in a child with autoimmunity and sterile chronic multifocal osteomyelitis evolving into disseminated granulomatous disease. J Clin Immunol. 2013 Nov; 33(8):1289-92. View in: PubMed

T lymphocyte abnormalities in juvenile systemic sclerosis patients. Clin Immunol. 2013 Oct; 149(1):146-55. View in: PubMed

Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013 Sep; 65(9):2486-96. View in: PubMed

Pediatric chronic nonbacterial osteomyelitis. Pediatrics. 2012 Nov; 130(5):e1190-7. View in: PubMed

Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012 Oct 16; 157(8):533-41. View in: PubMed

Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions. J Rheumatol. 2012 Oct; 39(10):2012-20. View in: PubMed

Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis. J Rheumatol. 2012 Aug; 39(8):1687-97. View in: PubMed

Pediatric rheumatic disease in the intensive care unit: Lessons learned from 15 years of experience in a tertiary care pediatric hospital. Pediatr Crit Care Med. 2012 May; 13(3):e181-6. View in: PubMed

Assessing the Performance of the Birmingham Vasculitis Activity Score at Diagnosis for Children with Antineutrophil Cytoplasmic Antibody-associated Vasculitis in A Registry for Childhood Vasculitis (ARChiVe). J Rheumatol. 2012 May; 39(5):1088-94. View in: PubMed

Acanthamoeba meningoencephalitis presenting as neuropsychiatric lupus in a pediatric patient. Clin Exp Rheumatol. 2012 Mar-Apr; 30(2):272-6. View in: PubMed

Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc Natl Acad Sci U S A. 2012 Jan 10; 109(2):E59-67. View in: PubMed

Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment. Biol Ther. 2012; 2:1. View in: PubMed

High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. 2012; 2012:765380. View in: PubMed

Scleroderma-like skin changes not involving the hand in a prepubertal male with type I diabetes mellitus: A case report. Dermatoendocrinol. 2011 Oct; 3(4):230-2. View in: PubMed

Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011 Sep; 63(9):1213-23. View in: PubMed

Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis. J Clin Immunol. 2011 Aug; 31(4):615-22. View in: PubMed

Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov; 62(11):3259-64. View in: PubMed

Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum. 2009 Nov; 60(11):3413-24. View in: PubMed

B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum. 2009 Nov; 60(11):3400-9. View in: PubMed

Ocular complications of childhood rheumatic diseases: nonuveitic inflammatory eye diseases. Curr Rheumatol Rep. 2009 Jul; 11(3):226-32. View in: PubMed

Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2009 Apr 14; 106(15):6256-61. View in: PubMed

High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum. 2009 Apr; 60(4):1085-95. View in: PubMed

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009 Feb; 28(2):129-37. View in: PubMed

Adalimumab in juvenile rheumatoid arthritis/juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2008 Sep; 4(5):549-58. View in: PubMed

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008 Aug 21; 359(8):810-20. View in: PubMed

Childhood quality of life in the changing landscape of pediatric rheumatology. J Pediatr (Rio J). 2008 Jul-Aug; 84(4):285-8. View in: PubMed

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008 May; 58(5):1496-504. View in: PubMed

Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum. 2007 Dec; 56(12):4164-73. View in: PubMed

Ocular complications of childhood rheumatic diseases: uveitis. Curr Rheumatol Rep. 2006 Dec; 8(6):459-68. View in: PubMed

Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum. 2006 Nov; 54(11):3573-82. View in: PubMed

Mutational analysis in neonatal-onset multisystem inflammatory disease: comment on the articles by Frenkel et al and Saito et al. Arthritis Rheum. 2006 Aug; 54(8):2703-4; author reply 2704-5. View in: PubMed

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006 Jun; 54(6):1987-94. View in: PubMed

Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006 May; 33(5):985-95. View in: PubMed

The use of anakinra in juvenile arthritis. Curr Rheumatol Rep. 2005 Dec; 7(6):434-40. View in: PubMed

Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005 May; 32(5):935-42. View in: PubMed

A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology. 2005 Apr; 10(2):79-93. View in: PubMed

Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol. 2004 Oct; 31(10):2055-61. View in: PubMed

Developments in the treatment of juvenile arthritis. Expert Opin Pharmacother. 2004 Jul; 5(7):1485-96. View in: PubMed

Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Rheum. 2004 Jun 15; 51(3):458-64. View in: PubMed

Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum. 2003 Aug 15; 49(4):501-7. View in: PubMed

Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum. 2003 Jul; 48(7):2079-80. View in: PubMed

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003 Jan; 48(1):218-26. View in: PubMed

Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am. 2002 Aug; 28(3):561-77, vi-vii. View in: PubMed

Powered bySC CTSI